Antitumor efficacy of the recombinant Newcastle disease virus rNDV-IL15 on melanoma models.
- Author:
Ze-Shan NIU
;
Fu-Liang BAI
;
Tian SUN
;
Hui TIAN
;
Jie-Chao YIN
;
Hong-Wei CAO
;
Dan YU
;
Gui-You TIAN
;
Yun-Zhou WU
;
De-Shan LI
;
Gui-Ping REN
- Publication Type:Journal Article
- MeSH:
Animals;
Body Weight;
Cell Line, Tumor;
Cell Proliferation;
Chick Embryo;
Cytotoxicity, Immunologic;
Female;
Genetic Therapy;
Interleukin-15;
genetics;
metabolism;
Melanoma, Experimental;
pathology;
therapy;
Mice;
Neoplasm Transplantation;
Newcastle disease virus;
genetics;
Plasmids;
Recombinant Proteins;
genetics;
metabolism;
Transfection;
Tumor Burden
- From:
Acta Pharmaceutica Sinica
2014;49(3):310-315
- CountryChina
- Language:Chinese
-
Abstract:
In order to enhance the antitumor efficacy of recombinant Newcastle disease virus, rNDV-IL15 was rescued in this study. Recombinant plasmid prNDV-IL15 was constructed, and BHK21 cells were transfected with the recombinant plasmid. Finally, the recombinant Newcastle disease virus rNDV-IL15 was successfully rescued. The growth curves of these two recombinant viruses were determined. Murine melanoma B16F10 cells were infected with rNDV-IL15 at MOI of 0.1, and the expression level of IL15 in the supernatant was detected by ELISA. The antitumor efficacy of rNDV-IL15 and rNDV was compared in vitro and in vivo. Results showed that prNDV-IL15 was constructed and recombinant virus rNDV-IL15 was successfully rescued. The growth curve of rNDV-IL15 showed that the growth of rNDV-IL15 had not been changed after insertion of IL15 gene. Results showed that there was high level of IL15 expression in the supernatant of rNDV-IL5-infected B16F10 cells (1 044.3 +/- 27.7 ng x mL(-1)). rNDV-IL15 and rNDV significantly inhibited the growth of B16F10 cells in vitro in a time-dependent manner. However, there was no significant difference between them. In animal experiments, rNDV-IL15 efficiently suppressed tumor growth in vivo when compared with rNDV, and the difference was statistically significant. The results suggested that rNDV-IL15 is a more effective antitumor agent.
